DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Amgen - 11 Eli Lilly - 10 — - 5 Jim Cramer - 5 Jim - 5 Jim Cramer's - 5 Cloudflare - 4 Jay Bradner - 3
Top related locs:
U.S Amgen New York City Novo billings America China Thousand Oaks , California
Top related orgs:
Apple - 11 CNBC - 8 Novo Nordisk - 7 Getty - 4 Nvidia - 4 New York Stock Exchange - 3 Dow - 3 Microsoft - 3

Search resuls for: "AMGEN"


25 mentions found


☆ Trade Tracker: The Investment Committee details their latest portfolio moves
  + stars: | 2024-05-17 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: The Investment Committee details their latest portfolio movesKevin Simpson and Steve Weiss explain their latest trades in Amgen, Duke Energy and Caterpillar.
Persons: Kevin Simpson, Steve Weiss Organizations: Duke Energy, Caterpillar Locations: Amgen
☆ The changing face of the Dow: See the names that have come and gone on the path to 40,000
  + stars: | 2024-05-16 | by ( Alex Harring Nick Wells | Alex Harring | Nick Wells | ) www.cnbc.com   time to read: +8 min
Stock Chart Icon Stock chart icon The Dow, all-timeThe average was created by Charles Dow in 1896 with just 12 industrial stocks. Paired with the Dow Jones Transportation Average , the two were collectively meant to offer a gauge for the broader economy. The sole caveat: No utility or transportation stocks are included, given the existence of the Dow Jones Utility Average and Transportation Average. 1972: Dow hits 1,000It may be hard to imagine given the recent achievement, but the Dow traded below 1,000 until the early 1970s. The Dow saw its worst year since 2008 in 2022, though 2023's rebound allowed the index to erase those losses.
Persons: Spencer Platt, Dow, Charles Dow, There's, Richard Nixon, Alcoa Esmark, Du Pont, Dow didn't, Walt Disney, Eastman Kodak Merck Alcoa ExxonMobil Phillip Morris, T General Motors Sears, Morgan, Phillip Morris, Walmart Du Pont J.P, Morgan Chase Walt, Donald Trump, General Electric Nike American Express Goldman Sachs, Morgan Chase, Johnson, Joe Biden, Trump, Goldman Sachs, Gamble Amgen, — Organizations: New York Stock Exchange, Getty, Dow Jones, Dow Jones Transportation, P Global, Dow, CNBC, General Foods, Harvester, Chevron, Procter, Gamble, Alcoa, Manville, ExxonMobil, Illinois Glass American Tobacco General Electric Procter, General Foods Sears Roebuck AT, T General Motors Texaco Bethlehem Steel, T General Motors Texaco Bethlehem Steel Goodyear Union Carbide Chevron Honeywell United Technologies Chrysler International Harvester US, Nickel Westinghouse Electric Eastman Kodak International, Woolworth, Oasis, Eastman Kodak Merck Alcoa ExxonMobil, Express General Electric Procter, Gamble AT, T General Motors, T General Motors Sears Roebuck Bethlehem Steel Goodyear Texaco Boeing Honeywell Union Carbide Caterpillar IBM United Technologies Chevron International, Walt Disney, Morgan Chase Westinghouse, Apple, Microsoft, Sears and Union Carbide, Eastman Kodak Johnson, Johnson Alcoa ExxonMobil, American Express General Electric Merck AT, T, Goodyear Procter & Gamble Caterpillar Hewlett, Packard Sears, Chevron Honeywell Union Carbide Citigroup IBM United Technologies, Walmart, Morgan Chase Walt Disney, Visa, Travelers, Nike, General Electric Nike American Express, General Electric Nike American Express Goldman Sachs Pfizer Apple Home Depot Procter, Gamble Boeing IBM Travelers Caterpillar Intel United Technologies Chevron, Morgan Chase UnitedHealth, Cisco Systems Johnson, Johnson Verizon, Cola McDonald’s, Du Pont Merck Walmart ExxonMobil Microsoft Corporation Walt Disney, Exxon Mobil, Walgreens Boots Alliance, Goldman Sachs Nike American Express Home Depot Procter, Gamble Amgen Honeywell, Apple Intel Travelers Cos Boeing IBM, Caterpillar Johnson, Johnson Verizon Chevron, Cisco Systems, Walgreens, Alliance Coca Cola Merck Walmart Dow Microsoft Walt Disney Locations: New York City, T General Motors Texaco Bethlehem Steel Goodyear, America
☆ F.D.A. Approves Drug for Persistently Deadly Form of Lung Cancer
  + stars: | 2024-05-16 | by ( Gina Kolata | ) www.nytimes.com   time to read: +1 min
The Food and Drug Administration on Thursday approved an innovative new treatment for patients with a form of lung cancer. It is to be used only by patients who have exhausted all other options to treat small cell lung cancer, and have a life expectancy of four to five months. The drug tarlatamab, or Imdelltra, made by the company Amgen, tripled patients’ life expectancy, giving them a median survival of 14 months after they took the drug. After decades with no real advances in treatments for small cell lung cancer, tarlatamab offers the first real hope, said Dr. Anish Thomas, a lung cancer specialist at the federal National Cancer Institute who was not involved in the trial. Dr. Timothy Burns, a lung cancer specialist at the University of Pittsburgh, said that the drug “will be practice-changing.”
Persons: tarlatamab, Anish Thomas, “, Timothy Burns, ” Organizations: Drug Administration, National Cancer Institute, University of Pittsburgh
☆ FDA approves Amgen's treatment for most deadly form of lung cancer
  + stars: | 2024-05-16 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
In clinical trials, Amgen's drug has been shown to reduce tumor growth and help people with small-cell lung cancer live significantly longer. Of the more than 2.2 million patients who are diagnosed with lung cancer worldwide each year, small-cell lung cancer comprises 15%, or 330,000, of those cases, Amgen said. There are around 35,000 patients with small-cell lung cancer in the U.S., Dr. Jay Bradner, Amgen's chief scientific officer, told CNBC. Small-cell lung cancer usually starts in the airways of the lung and grows rapidly, creating large tumors and spreading throughout the body. Maida Mangiameli, a small-cell lung cancer advocate and patient mentor from Naperville, Illinois, is also a survivor of the devastating disease.
Persons: Amgen, Jay Bradner, Bradner, Lynne Bell, Amgen's, Bell, I'm, Maida, Mangiameli, Amgen's Bradner Organizations: Drug Administration, of Cancer, CNBC, American Cancer Society Locations: U.S, Atlanta , Georgia, Naperville , Illinois
☆ Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
  + stars: | 2024-05-16 | by ( Jeff Marks | ) www.cnbc.com   time to read: +5 min
Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China
☆ Trade Tracker: Joe Terranova buys Amgen and Merck
  + stars: | 2024-05-15 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Joe Terranova buys Amgen and MerckJoe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys
Persons: Joe Terranova, Amgen, Merck Joe Terranova Organizations: Virtus Investment Partners
☆ Trade Tracker: Bill Baruch buys more Apple and Amgen
  + stars: | 2024-05-08 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Bill Baruch buys more Apple and AmgenBill Baruch, founder and president at Blue Line Capital, joins CNBC's 'Halftime Report' to discuss his latest trades.
Persons: Bill Baruch Organizations: Apple, Blue Line
☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
  + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com   time to read: +10 min
Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield
☆ Dr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or better
  + stars: | 2024-05-06 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or betterFormer FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Amgen's new injectable weight loss drugs, how it takes a different approach from other weight loss drugs like Wegovy and Mounjaro, state of the obesity drug market, and more.
Persons: Gottlieb, Scott Gottlieb Organizations: FDA
☆ What's driving this multiday rally, plus Jim Cramer's quick takes on 4 stocks
  + stars: | 2024-05-06 | by ( Jeff Marks | ) www.cnbc.com   time to read: +4 min
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stock gains continue: The market is higher on Monday, extending its gains over the past three sessions to nearly 3%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Jerome Powell, overbought, Jim Cramer's, Jim, Mellody Hobson, Howard Schultz, Laxman Narasimhan, Eli Lilly, Amgen, Lilly, Christian Organizations: CNBC, Stock, Starbucks, Worldwide Developers Conference, VisionPro, Nvidia, pharma, FDA, Simon Property Group, Club, Rockwell Automation, Jim Cramer's Charitable, Apple, Getty Locations: WWDC, Hamburg, Germany
☆ Generative AI will be designing new drugs all on its own in the near future
  + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com   time to read: +12 min
An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.
Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature
☆ Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and more
  + stars: | 2024-05-03 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +3 min
Hershey — Shares of the chocolate confectionary maker added about 1% after Hershey posted a first-quarter earnings beat. Hershey's $3.25 billion revenue also beat the $3.11 billion consensus. Amgen — Shares soared 13% after the biotech firm posted a first-quarter earnings and revenue beat. Cloudflare — The stock continued to sink, plunging 12% after reporting weak full-year guidance, although Cloudflare posted a first-quarter earnings and revenue beat. However, Coinbase's first-quarter revenue of $1.64 billion beat the $1.34 billion consensus, according to LSEG.
Persons: Hershey, LSEG, Apple, Eli Lilly, Cloudflare, Expedia, Piper Sandler, Fortinet, FactSet, Jefferies, Coinbase's, Benjamin Nolan, — CNBC's Brian Evans, Michelle Fox, Hakyung Kim, Tanaya Macheel Organizations: Hershey —, Apple, Novo Nordisk, BMO Capital Markets, Revenue, Arista Networks, Arista, LSEG . Union Pacific, JPMorgan Locations: billings, LSEG, Stifel
☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
  + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com   time to read: +3 min
The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.
Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America
☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
  + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +3 min
Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.
Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings
☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
  + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .
Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO
☆ Here's what's driving Friday's stock action in Apple, Coterra and Eli Lilly
  + stars: | 2024-05-03 | by ( Morgan Chittum | ) www.cnbc.com   time to read: +2 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is the kind of number you need that basically says the Fed is doing their job," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Coterra, naysayers, Eli Lilly, drugmaker Amgen, we're, Jim Cramer's, Jim Organizations: CNBC, Club, Apple, Coterra Energy, Mizuho Securities
☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
  + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.
Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S
☆ Stocks making the biggest moves after hours: Apple, Cloudflare, Expedia, Block and more
  + stars: | 2024-05-02 | by ( Pia Singh Darla Mercado | Cfp | Pia Singh | ) www.cnbc.com   time to read: +2 min
Check out the companies making headlines in after-hours trading: Apple — The iPhone maker advanced 7% as it announced a $110 billion share repurchase and a top- and bottom-line beat. That surpassed analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Expedia posted a beat on first-quarter revenue, which came in at $2.89 billion, surpassing analysts' estimates of $2.81 billion, per LSEG. Block reported adjusted earnings of 85 cents per share on revenue of $5.96 billion in the first quarter. Those results beat analysts' estimates for earnings of 72 cents per share and revenue of $5.82 billion, per LSEG.
Persons: Expedia, Amgen, LSEG, Fortinet, Cloudflare, DaVita, FactSet, —, Christina Cheddar, Berk Organizations: Apple Locations: billings
☆ Stock futures rise after Apple reports, traders look to April payrolls data: Live updates
  + stars: | 2024-05-02 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Futures tied to the Dow Jones Industrial Average gained 212 points, or 0.55%. S&P 500 futures rose nearly 0.3%, while Nasdaq 100 futures advanced about 0.5%. In extended trading, Apple advanced more than 6% after it announced a $110 billion share repurchase and a top -and bottom-line beat. The S&P 500 popped 0.91%, while the Dow gained 0.85%. The S&P 500 is off by 0.7% week to date, while the Nasdaq is down nearly 0.6%.
Persons: Cloudflare, Dow, Jerome Powell, Sonu Varghese, payrolls, Dow Jones Organizations: New York Stock Exchange, Stock, Dow Jones Industrial, Nasdaq, Apple, Biotech Amgen, Dow, Carson Group Locations: New York City, U.S
☆ Amgen scraps experimental weight loss pill, moves forward with injection
  + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.
Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo
☆ Stock futures rise after Fed decides to hold rates steady: Live updates
  + stars: | 2024-05-01 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Stock futures advanced Wednesday night as investors looked ahead to more corporate earnings due Thursday and key labor data set for later in the week. S&P 500 futures climbed 0.3%. Restaurant delivery service DoorDash dropped 15% after reporting a wider loss per share than Wall Street forecast. Those moves followed a choppy day on Wall Street as investors reacted to the Federal Reserve's decision to keep interest rates unchanged. The Dow finished about 0.2% higher, while the S&P 500 and Nasdaq Composite both closed the session lower by roughly 0.3%.
Persons: DoorDash, Jerome Powell, Eric Winograd, Winograd, Coinbase Organizations: Dow Jones Industrial, Nasdaq, Qualcomm, Federal, Dow, Apple, Moderna Locations: AllianceBernstein, Friday's
☆ 12 portfolio companies report earnings in the week ahead. What we want to hear from each
  + stars: | 2024-04-27 | by ( Zev Fima | ) www.cnbc.com   time to read: +15 min
The action quickly and sharply reversed back to the upside Friday after blowout earnings reports from Alphabet and Microsoft . In the week ahead, earnings are likely to drive the action again, though we'll get a few important macroeconomic reports. Earnings: We've got the biggest week of the earnings season ahead of us, with 12 Club holdings set to report. Eli Lilly 's report Tuesday morning continues to be all about sales of type-2 diabetes treatment Mounjaro and weight-loss drug Zepbound. In DuPont 's report Wednesday morning, we're looking for a continued rebound in its semiconductor business following a sequential increase last quarter.
Persons: Ford, we'll, Dow Jones, We've, Buckle, Eaton, Eli Lilly, Lilly, We're, Estee Lauder, Fabrizio Freda, we've, Linde, Bausch, Royal Philips, Woodward, SIRI, Archer, Johnson, Stanley Black, Decker, BAX, Cardinal Health, Parker, Belden, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Microsoft, Meta, Google Search, Big Tech, Nvidia, Broadcom, Ford Motor, Honeywell, Danaher, Labor Department, Labor, PMI, Services PMI, GE Healthcare, Amazon Web Services, Starbucks, Deutsche Bank, DuPont, Bausch Health, U.S ., Appeals, Apple, iPhones, Vision, ON Semiconductor, Resource Partners, Franklin Resources, Paramount, Transocean Ltd, Semiconductors, Arch Capital, Logitech International, Lattice Semiconductor, F5 Networks, Sanmina Corporation, GE HealthCare, PayPal, 3M Company, McDonalds, Enterprise Products Partners, Cola Company, Melco Resorts, Entertainment, SiriusXM Holdings, Oatly, American Electric Power Company, Leidos Holdings, Marathon Petroleum, Daniels, Midland Co, Equitrans Midstream Corporation, HSBC Holdings, HSBC, Devices, Caesars Entertainment, Lumen Technologies, Mondelez, Pfizer, CVS Health, Barrick, Mastercard Inc, Cruise Line Holdings Ltd, Kraft Heinz Company, Marriott International, Ares, Generac Holdings, Johnson Controls, Cenovus Energy Inc, Qualcomm, Devon Energy, Paycom, Axcelis Technologies, Coeur D'Alene Mines, Sunnova Energy International, MGM Resorts International, MGM, Solar Inc, Oil, Allstate, Co, Tenable Holdings, Enovix Corporation, Gladstone Capital, Avis Budget Group, eBay, EBAY, LIN, Novo Nordisk, Natural Resources, PENN Entertainment, Apache, ConocoPhillips, InMode Ltd, Baxter International, Cardinal, Regeneron Pharmaceuticals, Apollo Global Management, LLC, Cinemark Inc, Dominion Energy, Coterra Energy, Coinbase, Bill.com Holdings, Booking Holdings, United States Steel, AXT Inc, Materials, Energy, Hershey Company, XPO Logistics, Cboe, American Pipeline, Amneal Pharmaceuticals, Brookfield Business Partners, Brookfield Renewable Corporation, Magna International, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Bloomberg, Getty Locations: U.S, megaprojects, China, Eaton, Corning, Coeur D'Alene, Albemarle, ALB, Novo, New York
☆ Microsoft shares jump 4% after the big AI winner delivers in all the right places
  + stars: | 2024-04-25 | by ( Jim Cramer | ) www.cnbc.com   time to read: +9 min
However, momentum from AI services will keep Azure growth stabilized at these high levels, outperforming the market's expectations. AI services continue to be a large source of revenue growth, contributing seven percentage points of growth. The Office Commercial Products and Cloud Services revenue rose 12%, while the Office Consumer Products and Cloud Services revenue grew 4%. Windows Commercial Products and Cloud Services revenue increased 12%, driven by demand for Windows 365. The company guided Azure's constant currency revenue growth to 30% to 31%, which is higher than estimates of 29%.
Persons: OpenAI, Satya Nadella, there's, we're, Jim Cramer's, Jim Cramer, Jim, Satya Narayana Nadella, Lucas Jackson Organizations: Microsoft, Revenue, Google, Fortune, Productivity, Products, Cloud Services, Consumer Products, Novo Nordisk, Nvidia, Activision, Windows, Management, CNBC Locations: OpenAI, ChatGPT, Novo, Manhattan, New York City
☆ A pullback in this biotech stock has created a buying opportunity, according to the charts
  + stars: | 2024-04-22 | by ( Katie Stockton | ) www.cnbc.com   time to read: +2 min
Amgen has been in pullback mode since the beginning of February, losing roughly 13% within the context of its long-term uptrend. For those interested in "buying the dip," this may be a good time to revisit the stock, noting the decline looks overdone in the short term. There has been a positive reaction from AMGN to a short-term counter-trend "buy" signal from Tom DeMARK's TD Combo model, which supports a minimum two-week bounce. With Friday's reversal bar on AMGN's daily chart, combined with today's strength, our preferred momentum indicator the daily MACD is back on a "buy" signal. The MACD also shows a positive short-term divergence, supporting a bigger relief rally for AMGN in the near term.
Persons: Amgen, Tom DeMARK's Organizations: AMGN
☆ Final Trades: Shell, 2-YR T-Note and Amgen
  + stars: | 2024-04-12 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Shell, 2-YR T-Note and AmgenThe Investment Committee give you their top stocks to watch for the second half.
Organizations: Shell, Investment
0 next >>
Total: 25